Private equity has been buying up hospice centers - with striking consequences
By Jessica Hall
Medicare costs are higher and patients stay longer at hospice providers owned by private-equity firms, new research has found
Hospice provides care to people who are not expected to live longer than six months.
Hospice - providing care in the final days and weeks of a person's life - may not conjure up images of Wall Street, mergers and acquisitions, or big profit margins, but that's exactly what the $30 billion industry has become.
About 1.8 million Americans use hospice services each year, according to the Centers for Disease Control and Prevention. There are more than 5,800 hospice agencies in the U.S., three-quarters of which are for-profit entities, according to the CDC.
When a private-equity firm buys a hospice-care provider, costs jump, length of stay increases and the patient mix changes, a new study has found. In some cases, questions arose about whether patients were appropriately enrolled in hospice care in the first place, the researchers said.
Hospice provides care for people with terminal illnesses who have a prognosis of six months or less to live. The goal is to manage pain and symptoms, rather than curing the illness, in the patient's final months, weeks or days before death. For people 65 and older, Medicare pays for hospice services. For routine hospice care - which is provided in the home - Medicare pays $225 a day for the first two months and $177 per day thereafter.
However, Medicare spending on hospice care rose 5.9% following a private-equity acquisition, as the average length of stay increased by 6.3 days, according to the federally funded study published in the journal Health Affairs.
"The extent and magnitude of our findings surprised us," said Sneha Kannan, the lead author of the study and an assistant professor at the University of Pittsburgh. "We showed that acquisitions result in higher costs and increased length of stay."
The U.S. hospice market was about $31.2 billion in 2025 and is projected to reach $45.3 billion by 2033, growing at a compound annual growth rate of 4.8% from 2026 to 2033, according to Grand View Research.
In the study, the researchers compared 191 for-profit hospices acquired by private-equity firms between 2018 and 2022 with 1,305 similar for-profit hospices. After a private-equity acquisition, Medicare paid $993 more per hospice stay compared with comparable hospices. That's above the average baseline charge of $16,922.
In addition to the longer length of stay under hospice care, the patient profile changed to less medically needy - patients who need less hands-on care - and some patients also even exited hospice alive, the study found. That raised questions about whether they were appropriately enrolled in hospice in the first place, the researchers said.
"There may be inappropriate enrollment going on. Patients may have more than six months to live, which goes against the idea of hospice as end-of-life care," Kannan said. "In most care settings, a patient dies and that's not a good thing. But in hospice, the purpose is to care for them at the end of life."
The study also found that patients with dementia were admitted more often, suggesting that the private-equity hospices may have shifted toward patients who need less daily care than other patients, such as cancer patients who need active pain management. Having less needy patients is more profitable under Medicare's current method of payment, which pays a flat daily rate no matter the patient's diagnosis.
"It's possible it's the selection of patients," Kannan said. "It could be inappropriate enrollment."
The Centers for Medicare & Medicaid Services and the National Alliance for Care at Home, a hospice industry trade group, did not respond to requests for comment.
Medicare pays a set dollar amount per day regardless of the number of visits a patient gets or whether the care is provided by nurses, aides or social workers. The U.S. Government Accountability Office recently recommended that the payment method for hospice be revamped to pay for the number of patient visits rather than the number of days a patient spends in hospice.
Nonprofit hospice agencies have an annual profit margin of about 5% to 6%, while for-profit public or private-equity hospice firms sometimes have profit margins as high as 18% to 22%, according to a report by the University of Pennsylvania's Leonard Davis Institute of Health Economics.
The "hospice benefit is a rich benefit that can be quite profitable based on it largely being based on 'trust me,' in that you are given a daily rate regardless of visits, etc., and certain diagnoses with long lengths of stay are quite profitable. So [private equity] sees it as money maker," said Joan Teno, an adjunct professor of health services, policy and practice at Brown University and an expert on hospice.
Private equity "is based on quick turnover - some of the deals are just packaging hospices with high rates of live discharge, not making visits in the last days of life, and reselling. It is not improving the quality of care," Teno said.
The hospice industry has grown, in part due to the aging U.S. population. Medicare spending on hospice care nearly doubled from $15.5 billion in 2015 to $27.5 billion in 2024, according to MedPAC, the independent agency that advises Congress on Medicare issues. Yet the number of Medicare beneficiaries enrolled in the hospice grew at a slower rate of 32% - from 1.4 million in 2015 to 1.8 million in 2024, MedPAC found.
"Hospice is one of the most brilliant innovations of 20th-century healthcare. We watched as problems developed over the decades, and the crisis was utterly predictable and now has come to pass," said Ira Byock, a palliative-care physician, the author of several books on hospice and an emeritus professor at the Geisel School of Medicine at Dartmouth.
The hospice industry has come under increased scrutiny in the past few years. CMS last week extended for an additional six months a national moratorium on hospice-provider enrollment in Medicare in an effort to combat fraud.
One of the biggest problems with hospice is the lack of explicit standards for key quality-of-care metrics such as appropriate caseloads, response time for emergencies, or even protocols on how to handle emergencies such as a patient with extreme pain or seizures, Byock said.
"Consumers have no power. For the most part, it's let the 'die-er' beware," Byock said. "Ownership shouldn't matter. What should matter is demonstrable levels of quality."
-Jessica Hall
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-22-26 1222ET
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

The 10 Best Dividend Stocks

5 Stocks to Buy After Earnings

2 5-Star Stocks to Buy at Big Discounts

Tech Stocks Suffer Worst Week Since 2020 as Anthropic Faces Day Two Decline

